Search results: Sage Journals

Restricted accessResearch articleFirst published December, 2009

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177 Lu-DOTATATE and 90 Y-DOTATOC

Maribel L. Sierra, Alberto Agazzi, Lisa Bodei [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published February, 2007

From Outside to Inside? Dose-Dependent Renal Tubular Damage After High-Dose Peptide Receptor Radionuclide Therapy in Rats Measured with In Vivo 99m Tc-DMSA-SPECT and Molecular Imaging

Flavio Forrer, Edgar Rolleman, Magda Bijster [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessEditorialFirst published October, 2010

Pretherapy Prediction of Nephrotoxicity After Peptide Radionuclide Receptor Therapy (PRRT)

Gerald L. DeNardo, Daniel J. Macey

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published December 1, 2008

Normative data and test-retest reliability of the sinusoidal harmonic acceleration test,pseudorandom rotation test and velocity step test

Leen Maes, Ingeborg Dhooge, Eddy De Vel [...]

Journal of Vestibular Research

Restricted accessResearch articleFirst published April, 2004

Radiolabeled Carbohydrated Somatostatin Analogs: A Review of the Current Status

Hans-Jürgen Wester, Margret Schottelius, Thorsten Poethko [...]

Cancer Biotherapy and Radiopharmaceuticals

Open accessResearch articleFirst published 2022

Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna

Philipp Melhorn, Elisabeth Kretschmer-Chott, Ladislaia Wolff [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published April, 2022

Estimation of Absorbed Doses of Indigenously Produced “Direct-route” Lutetium-177-[ 177 Lu]Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [ 177 Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles

Kamaldeep, Gaurav Wanage, Sarvesh Loharkar [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessBrief reportFirst published June, 2021

Severe metabolic acidosis and hyperkalemia after peptide receptor radionuclide therapy. A case report,review of the literature and proposed treatment algorithm

Nikolaos A Trikalinos, Hyun Kim, Amir Iravani [...]

Journal of Onco-Nephrology

Restricted accessResearch articleFirst published October, 2021

177 Lu-dotatate use in chronic kidney disease patients: A single center experience

Sandhya Manohar, Panagiotis Kompotiatis, Thorvardur R Halfdanarson [...]

Journal of Onco-Nephrology

Restricted accessReview articleFirst published March, 2015

Peptide Receptor Radionuclide Therapy: An Overview

Ashutosh Dash, Sudipta Chakraborty, Maroor Raghavan Ambikalmajan Pillai [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published December, 2009

Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177 Lu-DOTATATE and 90 Y-DOTATOC

Maribel L. Sierra, Alberto Agazzi, Lisa Bodei [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published February, 2007

From Outside to Inside? Dose-Dependent Renal Tubular Damage After High-Dose Peptide Receptor Radionuclide Therapy in Rats Measured with In Vivo 99m Tc-DMSA-SPECT and Molecular Imaging

Flavio Forrer, Edgar Rolleman, Magda Bijster [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessEditorialFirst published October, 2010

Pretherapy Prediction of Nephrotoxicity After Peptide Radionuclide Receptor Therapy (PRRT)

Gerald L. DeNardo, Daniel J. Macey

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessResearch articleFirst published December 1, 2008

Normative data and test-retest reliability of the sinusoidal harmonic acceleration test,pseudorandom rotation test and velocity step test

Leen Maes, Ingeborg Dhooge, Eddy De Vel [...]

Journal of Vestibular Research

Restricted accessResearch articleFirst published April, 2004

Radiolabeled Carbohydrated Somatostatin Analogs: A Review of the Current Status

Hans-Jürgen Wester, Margret Schottelius, Thorsten Poethko [...]

Cancer Biotherapy and Radiopharmaceuticals

Open accessResearch articleFirst published 2022

Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna

Philipp Melhorn, Elisabeth Kretschmer-Chott, Ladislaia Wolff [...]

Therapeutic Advances in Medical Oncology

Restricted accessResearch articleFirst published April, 2022

Estimation of Absorbed Doses of Indigenously Produced “Direct-route” Lutetium-177-[ 177 Lu]Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [ 177 Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles

Kamaldeep, Gaurav Wanage, Sarvesh Loharkar [...]

Cancer Biotherapy and Radiopharmaceuticals

Restricted accessBrief reportFirst published June, 2021

Severe metabolic acidosis and hyperkalemia after peptide receptor radionuclide therapy. A case report,review of the literature and proposed treatment algorithm

Nikolaos A Trikalinos, Hyun Kim, Amir Iravani [...]

Journal of Onco-Nephrology

Restricted accessResearch articleFirst published October, 2021

177 Lu-dotatate use in chronic kidney disease patients: A single center experience

Sandhya Manohar, Panagiotis Kompotiatis, Thorvardur R Halfdanarson [...]

Journal of Onco-Nephrology

Restricted accessReview articleFirst published March, 2015

Peptide Receptor Radionuclide Therapy: An Overview

Ashutosh Dash, Sudipta Chakraborty, Maroor Raghavan Ambikalmajan Pillai [...]

Cancer Biotherapy and Radiopharmaceuticals